Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Acne
Interventions
DRUG

Epiduo vehicle gel

500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks

DRUG

CD07223

500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks

DRUG

CD07223

500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks

DRUG

Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel

500 microliters Epiduo Gel on one of the half-face for the morning dose

Trial Locations (9)

24501

Education and Research Foundation, Inc, Lynchburg

27103

Piedmont Medical Research, Winston-Salem

40202

Dermatology Specialist PSC, Louisville

48088

Grekin Skin Institute, Warren

58104

Cetero, Fargo

77845

J & S Studies, Bryan

78759

Derm Research, Inc, Austin

Unknown

Burke Pharmaceuticals, Hot Springs

07662

TKL Research, Rochelle Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT01106807 - Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne | Biotech Hunter | Biotech Hunter